Prothena Corporation PLC
PRTA
View Detailed Chart
10.560USD
+0.480+4.76%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
568.44MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.76%
5 Days
-1.77%
1 Month
+2.03%
6 Months
+48.73%
Year to Date
-23.75%
1 Year
-40.34%
View Detailed Chart
TradingKey Stock Score of Prothena Corporation PLC
Currency: USD Updated: 2025-11-07Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prothena Corporation PLC's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Hold
Current Rating
18.333
Target Price
+73.61%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Prothena Corporation PLC Highlights
StrengthsRisks
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 150.73% year-on-year.
Overvalued
The company’s latest PE is -2.03, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.66M shares, decreasing 25.62% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 3.67K shares of this stock.
Prothena Corporation PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Prothena Corporation PLC Info
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Ticker SymbolPRTA
CompanyProthena Corporation PLC
CEODr. Gene G. Kinney, Ph.D.
Websitehttps://www.prothena.com/
Related Instruments
-1.43%
-0.22%
+0.06%
+0.97%
-0.17%
+0.59%
+1.46%
-1.83%
-3.70%
+0.06%
+0.34%
-0.77%
-1.63%
+0.16%
-1.00%
+0.58%
0.00%
+1.65%
+0.50%
+0.57%Popular Symbols
